|Day's Range||4.01 - 4.04|
|52 Week Range||3.95 - 8.35|
|PE Ratio (TTM)||6.01|
|Earnings Date||Aug 8, 2017 - Aug 14, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||7.00|
LONDON, UK / ACCESSWIRE / June 30, 2017 / Pro-Trader Daily has lined up these stocks for our daily research reports coverage. Before the markets open, Pro-TD makes a brief technical snapshot of select ...
Nuvo Pharmaceuticals™ Inc. Announces Topline Results from European Ankle Sprain Study with Pennsaid® 2%
MISSISSAUGA, ON, May 15, 2017 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (NRI.TO), a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today reported topline results from its multi-centre, randomized, placebo-controlled, double-blind, parallel group trial in patients, with grade I or II ankle sprains (the Trial) and in particular reported that the Trial had failed to meet its primary endpoint.